Mélanie Serrero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mélanie Serrero has a total of 292 co-authors. Here are the top co-authors by number of shared publications:
- Stéphane Nancey
Department of Gastroenterology, University Claude Bernard Lyon 1, Hospices Civils de Lyon, CHU Lyon-Sud, University Lyon1 and INSERM U1111, CIRI , Lyon
12 shared publications - Anthony Buisson
Service d’Hépato-Gastroentérologie, CHU Clermont-Ferrand, Inserm, 3iHP, Université Clermont Auvergne, Clermont-Ferrand, France
11 shared publications - Aurelien Amiot
Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, 94805, Villejuif, France; Department of Gastroenterology, University Hospital of Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France
10 shared publications - Lucine Vuitton
Department of Gastroenterology, University Hospital of Besançon and UMR 1098 Right INSERM, EFS Bourgogne-Franche-Comté and University of Franche-Comté, France
10 shared publications - Mathurin Fumery
Department of gastroenterology, Amiens University Hospital, Amiens, France
10 shared publications - Romain Altwegg
Department of Hepatogastroenterology, CHU St Eloi Montpellier, Montpellier, France
10 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (4) , 479-487
Association between physical activity with disease activity and functional disability in patients with inflammatory bowel disease
- 3 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (4) , 479-487
Open AccessAssociation between physical activity with disease activity and functional disability in patients with inflammatory bowel disease
- Open Access
- 30 December 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (2) , 220-231
Diet and clinical remission in patients with inflammatory bowel disease: A multicenter cross-sectional study
- 30 December 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (2) , 220-231
Open AccessDiet and clinical remission in patients with inflammatory bowel disease: A multicenter cross-sectional study
- Open Access
- 8 December 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00954
Impact of Endometriosis on the Progression of Inflammatory Bowel Diseases: A Multicenter Retrospective Study
INTRODUCTION: Women with endometriosis have a higher risk of developing inflammatory bowel diseases (IBDs). This study aimed to better understanding the impact of endometriosis on the course of IBD. METHODS: We conducted a retrospective cohort study in 18 French and Belgian IBD centers between June 2022 and March 2023. Any patient with both conditions was eligible for inclusion. They were randomly matched to 1 or 2 patients with IBD without endometriosis. The impact on IBD progression was assessed using a composite severity criterion including intestinal damage or need for bowel surgery. RESULTS: Overall, 207 patients with both conditions (149 Crohn's disease [CD]; 58 ulcerative colitis [UC]) were matched to 409 patients with IBD alone. The median follow-up duration for IBD was 10 years (5.75–17). No difference was observed between the 2 groups regarding CD location, disease phenotype, and anoperineal involvement. Proctitis were more frequent in patients with UC and endometriosis. Patients with IBD with endometriosis were significantly less exposed to immunosuppressants (UC P < 0.01; CD P < 0.001) and biologics (UC P < 0.01; CD P < 0.001). Patients with CD with endometriosis had a less severe disease course compared with patients without endometriosis (hazard ratio 0.68, 95% confidence interval 0.50–0.92, P = 0.011). Patients with UC with endometriosis had not a significant different disease course compared with patients without endometriosis (hazard ratio 1.73, 95% confidence interval 0.74–4.00, P = 0.20). These results were similar in the subgroup of patients with endometriosis treated surgically. DISCUSSION: Endometriosis does not negatively influence the course of IBD, patients with CD even have a less severe progression. Patients were significantly less exposed to immunosuppressants and biologics.
- 8 December 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00954
Open AccessImpact of Endometriosis on the Progression of Inflammatory Bowel Diseases: A Multicenter Retrospective Study
INTRODUCTION: Women with endometriosis have a higher risk of developing inflammatory bowel diseases (IBDs). This study aimed to better understanding the impact of endometriosis on the course of IBD. METHODS: We conducted a retrospective cohort study in 18 French and Belgian IBD centers between June 2022 and March 2023. Any patient with both conditions was eligible for inclusion. They were randomly matched to 1 or 2 patients with IBD without endometriosis. The impact on IBD progression was assessed using a composite severity criterion including intestinal damage or need for bowel surgery. RESULTS: Overall, 207 patients with both conditions (149 Crohn's disease [CD]; 58 ulcerative colitis [UC]) were matched to 409 patients with IBD alone. The median follow-up duration for IBD was 10 years (5.75–17). No difference was observed between the 2 groups regarding CD location, disease phenotype, and anoperineal involvement. Proctitis were more frequent in patients with UC and endometriosis. Patients with IBD with endometriosis were significantly less exposed to immunosuppressants (UC P < 0.01; CD P < 0.001) and biologics (UC P < 0.01; CD P < 0.001). Patients with CD with endometriosis had a less severe disease course compared with patients without endometriosis (hazard ratio 0.68, 95% confidence interval 0.50–0.92, P = 0.011). Patients with UC with endometriosis had not a significant different disease course compared with patients without endometriosis (hazard ratio 1.73, 95% confidence interval 0.74–4.00, P = 0.20). These results were similar in the subgroup of patients with endometriosis treated surgically. DISCUSSION: Endometriosis does not negatively influence the course of IBD, patients with CD even have a less severe progression. Patients were significantly less exposed to immunosuppressants and biologics.
- Open Access
- 1 August 2023
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 14 (12) , e00607
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif
INTRODUCTION: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort. METHODS: We conducted a cross-sectional study in 30 French referral centers. Between May 2021 and June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire. RESULTS: A total of 1,971 consecutive patients with IBD were analyzed. There were 1,056 women (53.8%), and the median age of patients was 41 years (31–54). The median disease duration was 11 years (1–18). Overall, 544 (27.6%) had at least 1 EIM. In 20.2% of cases, patients had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (odds ratio [OR] = 2.56; P < 0.001) was a risk factor of EIM, while the Montreal A3 classification (OR = 0.61, P = 0.023) and male gender (OR = 0.61, P < 0.001) were associated with a lower risk of EIM occurrence. IBD current clinical remission (OR = 2.42; P < 0.001) and smoking cessation (OR = 2.98; P < 0.001) were associated factors of EIM remission. Conversely, age at IBD diagnosis (OR = 0.98; P < 0.018) was associated with a lower risk of EIM remission. DISCUSSION: One quarter of patients had at least 1 EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission.
- 1 August 2023
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 14 (12) , e00607
Open AccessPrevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif
INTRODUCTION: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort. METHODS: We conducted a cross-sectional study in 30 French referral centers. Between May 2021 and June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire. RESULTS: A total of 1,971 consecutive patients with IBD were analyzed. There were 1,056 women (53.8%), and the median age of patients was 41 years (31–54). The median disease duration was 11 years (1–18). Overall, 544 (27.6%) had at least 1 EIM. In 20.2% of cases, patients had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (odds ratio [OR] = 2.56; P < 0.001) was a risk factor of EIM, while the Montreal A3 classification (OR = 0.61, P = 0.023) and male gender (OR = 0.61, P < 0.001) were associated with a lower risk of EIM occurrence. IBD current clinical remission (OR = 2.42; P < 0.001) and smoking cessation (OR = 2.98; P < 0.001) were associated factors of EIM remission. Conversely, age at IBD diagnosis (OR = 0.98; P < 0.018) was associated with a lower risk of EIM remission. DISCUSSION: One quarter of patients had at least 1 EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission.
- 14 May 2022
- Published by Elsevier in Digestive and Liver Disease
- Vol. 54 (10) , 1350-1357
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID
- 14 May 2022
- Published by Elsevier in Digestive and Liver Disease
- Vol. 54 (10) , 1350-1357
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID
- Open Access
- 1 January 2022
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 16 (Supplement) , i537
P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study
The emergence of biologics has significantly improved the course of inflammatory bowel diseases (IBD) despite a potential higher risk of infections. Use of biologics in the elderly population remains a challenge since elderly patients are at higher risk of infection. Anti-tumor necrosis factor (anti-TNF), vedolizumab and ustekinumab are all potentially susceptible to increase the risk of infection. We conducted a one-year, prospective, multicenter, observational study comparing the respective infectious risk under anti-TNF, vedolizumab or ustekinumab in elderly patients with IBD. All IBD patients over 65 years, from six medical centers and receiving anti-TNF (first group), vedolizumab or ustekinumab (second group, defined as new biologics) treatment were included. The primary endpoint was the prevalence of at least one infection during follow-up. The cumulative risk of severe infection requiring hospitalization was recorded. The study included 207 consecutive patients, 113 under anti-TNF and 94 patients under vedolizumab or ustekinumab (median age 71 years, 112 with Crohn’s disease and 95 with ulcerative colitis). There was no difference concerning combination therapy, steroids use and the Charlson index between the two groups. The prevalence of infections was similar in patients under anti-TNF (29%) and in those under vedolizumab and ustekinumab (28%) (p=0.81). There was no difference in terms of type of infection, infection-related hospitalization (7% vs 6.4%), antibiotic prescription and treatment efficacy between the two groups. In patients over 75 years of age (n=50), the prevalence of infections was comparable in both groups. Around 30 % of elderly patients with IBD under biologics experienced at least one infection during the one-year study period. The risk does not differ between patients treated with anti-TNF and those under vedolizumab or ustekinumab.
- 1 January 2022
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 16 (Supplement) , i537
Open AccessP604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study
The emergence of biologics has significantly improved the course of inflammatory bowel diseases (IBD) despite a potential higher risk of infections. Use of biologics in the elderly population remains a challenge since elderly patients are at higher risk of infection. Anti-tumor necrosis factor (anti-TNF), vedolizumab and ustekinumab are all potentially susceptible to increase the risk of infection. We conducted a one-year, prospective, multicenter, observational study comparing the respective infectious risk under anti-TNF, vedolizumab or ustekinumab in elderly patients with IBD. All IBD patients over 65 years, from six medical centers and receiving anti-TNF (first group), vedolizumab or ustekinumab (second group, defined as new biologics) treatment were included. The primary endpoint was the prevalence of at least one infection during follow-up. The cumulative risk of severe infection requiring hospitalization was recorded. The study included 207 consecutive patients, 113 under anti-TNF and 94 patients under vedolizumab or ustekinumab (median age 71 years, 112 with Crohn’s disease and 95 with ulcerative colitis). There was no difference concerning combination therapy, steroids use and the Charlson index between the two groups. The prevalence of infections was similar in patients under anti-TNF (29%) and in those under vedolizumab and ustekinumab (28%) (p=0.81). There was no difference in terms of type of infection, infection-related hospitalization (7% vs 6.4%), antibiotic prescription and treatment efficacy between the two groups. In patients over 75 years of age (n=50), the prevalence of infections was comparable in both groups. Around 30 % of elderly patients with IBD under biologics experienced at least one infection during the one-year study period. The risk does not differ between patients treated with anti-TNF and those under vedolizumab or ustekinumab.
- 1 December 2021
- Published by Elsevier in Revue du Rhumatisme
- Vol. 88, A52-A53
COMBIO : efficacité et tolérance des associations de thérapies ciblées chez les patients atteints de maladies inflammatoires à médiation immunitaire
- 1 December 2021
- Published by Elsevier in Revue du Rhumatisme
- Vol. 88, A52-A53
COMBIO : efficacité et tolérance des associations de thérapies ciblées chez les patients atteints de maladies inflammatoires à médiation immunitaire
- 1 April 2021
- Published by Elsevier in Digestive and Liver Disease
- Vol. 53 (4) , 434-441
Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group
- 1 April 2021
- Published by Elsevier in Digestive and Liver Disease
- Vol. 53 (4) , 434-441
Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group